Philip Scheltens

186.7k total citations · 32 hit papers
1.2k papers, 100.6k citations indexed

About

Philip Scheltens is a scholar working on Psychiatry and Mental health, Physiology and Cognitive Neuroscience. According to data from OpenAlex, Philip Scheltens has authored 1.2k papers receiving a total of 100.6k indexed citations (citations by other indexed papers that have themselves been cited), including 701 papers in Psychiatry and Mental health, 495 papers in Physiology and 273 papers in Cognitive Neuroscience. Recurrent topics in Philip Scheltens's work include Dementia and Cognitive Impairment Research (674 papers), Alzheimer's disease research and treatments (463 papers) and Functional Brain Connectivity Studies (200 papers). Philip Scheltens is often cited by papers focused on Dementia and Cognitive Impairment Research (674 papers), Alzheimer's disease research and treatments (463 papers) and Functional Brain Connectivity Studies (200 papers). Philip Scheltens collaborates with scholars based in Netherlands, United Kingdom and United States. Philip Scheltens's co-authors include Frederik Barkhof, Wiesje M. van der Flier, Cornelis J. Stam, Serge A.R.B. Rombouts, Clifford R. Jack, Martin N. Rossor, Yolande A.L. Pijnenburg, María C. Carrillo, John C. Morris and David S. Knopman and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Lancet and Nature Medicine.

In The Last Decade

Philip Scheltens

1.2k papers receiving 98.7k citations

Hit Papers

The diagnosis of dementia due to Alzh... 1992 2026 2003 2014 2011 2006 2007 2016 2005 4.0k 8.0k 12.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
    2011 13.8k citations Claudia H. Kawas, Philip Scheltens et al. profile →
  2. Consistent resting-state networks across healthy subjects
    2006 3.4k citations Serge A.R.B. Rombouts, Frederik Barkhof et al. profile →
  3. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria
    2007 3.2k citations Howard Feldman, Jeffrey L. Cummings et al. profile →
  4. Alzheimer's disease
    2016 2.4k citations Philip Scheltens, Wiesje M. van der Flier et al. profile →
  5. Risk of dementia in diabetes mellitus: a systematic review
    2005 1.7k citations Philip Scheltens et al. profile →
  6. A New Rating Scale for Age-Related White Matter Changes Applicable to MRI and CT
    2001 1.4k citations Frederik Barkhof, Philip Scheltens et al. profile →
  7. The clinical use of structural MRI in Alzheimer disease
    2010 1.4k citations Philip Scheltens et al. profile →
  8. Atrophy of medial temporal lobes on MRI in "probable" Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates.
    1992 1.3k citations Philip Scheltens, Frederik Barkhof et al. profile →
  9. A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers
    2016 1.2k citations Howard Feldman, Philip Scheltens et al. Neurology profile →
  10. Small-World Networks and Functional Connectivity in Alzheimer's Disease
    2006 998 citations Philip Scheltens et al. profile →
  11. Reduced resting-state brain activity in the “default network” in normal aging
    2007 968 citations Frederik Barkhof, Philip Scheltens et al. profile →
  12. White matter hyperintensities, cognitive impairment and dementia: an update
    2015 856 citations Philip Scheltens et al. profile →
  13. A semiquantative rating scale for the assessment of signal hyperintensities on magnetic resonance imaging
    1993 787 citations Philip Scheltens, Frederik Barkhof et al. profile →
  14. Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup
    2024 776 citations Oskar Hansson, Philip Scheltens et al. profile →
  15. Graph theoretical analysis of magnetoencephalographic functional connectivity in Alzheimer's disease
    2008 707 citations Philip Scheltens et al. profile →
  16. Altered resting state networks in mild cognitive impairment and mild Alzheimer's disease: An fMRI study
    2005 606 citations Serge A.R.B. Rombouts, Frederik Barkhof et al. profile →
  17. Heterogeneity of small vessel disease: a systematic review of MRI and histopathology correlations
    2010 570 citations Alida A. Gouw, Wiesje M. van der Flier et al. profile →
  18. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer’s Association Research Roundtable Workgroup
    2011 554 citations Philip Scheltens, Howard Feldman et al. profile →
  19. Diagnostic Criteria for Vascular Cognitive Disorders
    2014 543 citations Philip Scheltens et al. profile →
  20. Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis
    1998 519 citations Philip Scheltens, Frederik Barkhof et al. Neurology profile →
  21. The effect of physical activity on cognitive function in patients with dementia: A meta-analysis of randomized control trials
    2015 430 citations Bart N.M. van Berckel, Philip Scheltens et al. profile →
  22. Vascular cognitive impairment
    2018 412 citations Wiesje M. van der Flier, Philip Scheltens et al. profile →
  23. A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease
    2017 411 citations Philip Scheltens, Frederik Barkhof et al. Alzheimer s Research & Therapy profile →
  24. Timely Diagnosis for Alzheimer’s Disease: A Literature Review on Benefits and Challenges
    2015 388 citations Philip Scheltens et al. profile →
  25. Current state of Alzheimer’s fluid biomarkers
    2018 375 citations Jeffrey L. Cummings, Philip Scheltens et al. profile →
  26. On the path to 2025: understanding the Alzheimer’s disease continuum
    2017 369 citations Jeffrey L. Cummings, Philip Scheltens et al. Alzheimer s Research & Therapy profile →
  27. Drug development in Alzheimer’s disease: the path to 2025
    2016 346 citations Jeffrey L. Cummings, Philip Scheltens et al. Alzheimer s Research & Therapy profile →
  28. The probabilistic model of Alzheimer disease: the amyloid hypothesis revised
    2021 290 citations Rik Ossenkoppele, Jeffrey L. Cummings et al. profile →
  29. Amsterdam Dementia Cohort: Performing Research to Optimize Care
    2018 220 citations Wiesje M. van der Flier, Philip Scheltens profile →
  30. The clinical promise of biomarkers of synapse damage or loss in Alzheimer’s disease
    2020 208 citations John Harrison, Philip Scheltens et al. Alzheimer s Research & Therapy profile →
  31. Gut Microbiota Composition Is Related to AD Pathology
    2022 149 citations Francisca A. de Leeuw, Astrid S. Doorduijn et al. profile →
  32. evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer’s disease
    2025 40 citations Jeffrey L. Cummings, Alireza Atri et al. Alzheimer s Research & Therapy profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Philip Scheltens Netherlands 137 43.9k 36.4k 29.8k 18.2k 16.3k 1.2k 100.6k
David S. Knopman United States 142 47.4k 1.1× 40.8k 1.1× 23.0k 0.8× 14.8k 0.8× 11.4k 0.7× 1.0k 94.0k
Ronald C. Petersen United States 157 61.2k 1.4× 51.4k 1.4× 29.4k 1.0× 18.2k 1.0× 14.3k 0.9× 1.1k 117.0k
Clifford R. Jack United States 152 53.7k 1.2× 46.2k 1.3× 29.9k 1.0× 16.1k 0.9× 23.0k 1.4× 1.2k 105.5k
John C. Morris United States 148 48.0k 1.1× 44.1k 1.2× 24.6k 0.8× 15.1k 0.8× 11.2k 0.7× 999 116.2k
Michael W. Weiner United States 132 30.7k 0.7× 27.8k 0.8× 19.9k 0.7× 10.4k 0.6× 16.8k 1.0× 890 71.2k
Bruce L. Miller United States 146 31.9k 0.7× 28.9k 0.8× 28.8k 1.0× 12.4k 0.7× 9.4k 0.6× 1.1k 90.5k
William J. Jagust United States 114 32.4k 0.7× 27.9k 0.8× 20.3k 0.7× 9.8k 0.5× 10.5k 0.6× 481 61.5k
Frederik Barkhof Netherlands 142 17.3k 0.4× 12.8k 0.4× 17.7k 0.6× 11.5k 0.6× 21.0k 1.3× 1.4k 88.8k
Steven T. DeKosky United States 111 29.5k 0.7× 25.4k 0.7× 11.8k 0.4× 9.2k 0.5× 5.2k 0.3× 549 64.0k
Guy M. McKhann United States 90 26.7k 0.6× 22.7k 0.6× 14.1k 0.5× 8.0k 0.4× 5.3k 0.3× 452 67.9k

Countries citing papers authored by Philip Scheltens

Since Specialization
Citations

This map shows the geographic impact of Philip Scheltens's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Philip Scheltens with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Philip Scheltens more than expected).

Fields of papers citing papers by Philip Scheltens

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Philip Scheltens. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Philip Scheltens. The network helps show where Philip Scheltens may publish in the future.

Co-authorship network of co-authors of Philip Scheltens

This figure shows the co-authorship network connecting the top 25 collaborators of Philip Scheltens. A scholar is included among the top collaborators of Philip Scheltens based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Philip Scheltens. Philip Scheltens is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Venkatraghavan, Vikram, Wiesje M. van der Flier, Yolande A.L. Pijnenburg, et al.. (2025). Enlarged cavum septum pellucidum as a neuroimaging signature of head impact exposure. Brain Communications. 7(2). fcaf085–fcaf085. 1 indexed citations
2.
Cummings, Jeffrey L., Alireza Atri, Howard Feldman, et al.. (2025). evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer’s disease. Alzheimer s Research & Therapy. 17(1). 14–14. 40 indexed citations breakdown →
3.
Wang, Sheng‐Min, Dong Woo Kang, Yoo Hyun Um, et al.. (2024). Plasma oligomer beta-amyloid is associated with disease severity and cerebral amyloid deposition in Alzheimer’s disease spectrum. Alzheimer s Research & Therapy. 16(1). 55–55. 8 indexed citations
4.
Ebenau, Jarith L., Denise Visser, Argonde C. van Harten, et al.. (2022). Longitudinal change in ATN biomarkers in cognitively normal individuals. Alzheimer s Research & Therapy. 14(1). 124–124. 6 indexed citations
5.
Tesi, Niccoló, Marc Hulsman, Iris E. Jansen, et al.. (2021). Pathway-specific polygenic risk score of AD-associated genetic variants associated with AD risk, resilience against AD, and progression to AD. Pure Amsterdam UMC. 1 indexed citations
6.
Pelkmans, Wiesje, Nienke Legdeur, Mara ten Kate, et al.. (2021). Amyloid‐β, cortical thickness, and subsequent cognitive decline in cognitively normal oldest‐old. Annals of Clinical and Translational Neurology. 8(2). 348–358. 11 indexed citations
7.
Ingala, Silvia, Jori Tomassen, Dennis van ‘t Ent, et al.. (2021). Amyloid-driven disruption of default mode network connectivity in cognitively healthy individuals. Brain Communications. 3(4). fcab201–fcab201. 28 indexed citations
8.
Reimand, Juhan, et al.. (2020). Association of amyloid-β CSF/PET discordance and tau load 5 years later. Neurology. 95(19). e2648–e2657. 31 indexed citations
9.
Tesi, Niccoló, Sven J. van der Lee, Marc Hulsman, et al.. (2020). Immune response and endocytosis pathways are associated with the resilience against Alzheimer’s disease. Translational Psychiatry. 10(1). 332–332. 34 indexed citations
10.
Doorduijn, Astrid S., Marjolein Visser, Ondine van de Rest, et al.. (2019). Associations of AD Biomarkers and Cognitive Performance with Nutritional Status: The NUDAD Project. Nutrients. 11(5). 1161–1161. 29 indexed citations
11.
Legdeur, Nienke, Pieter Jelle Visser, Davis C. Woodworth, et al.. (2019). White Matter Hyperintensities and Hippocampal Atrophy in Relation to Cognition: The 90+ Study. Journal of the American Geriatrics Society. 67(9). 1827–1834. 32 indexed citations
12.
Gardiner, Sarah L., Aster V. E. Harder, Stella Trompet, et al.. (2018). Repeat length variations in ATXN1 and AR modify disease expression in Alzheimer's disease. Neurobiology of Aging. 73. 230.e9–230.e17. 5 indexed citations
13.
Boeckhout, Martin, Philip Scheltens, Peggy Manders, et al.. (2017). Patients to learn from: on the need for systematic integration of research and care in academic health care. Journal of Clinical and Translational Research. 1 indexed citations
14.
Scheltens, Philip, et al.. (2017). [DNA diagnostics in dementia].. PubMed. 161. D1774–D1774. 1 indexed citations
15.
Harten, Argonde C. van, Wesley Jongbloed, Charlotte E. Teunissen, et al.. (2017). CSF ApoE predicts clinical progression in nondemented APOEε4 carriers. Neurobiology of Aging. 57. 186–194. 19 indexed citations
16.
Cohn‐Hokke, Petra E., Henne Holstege, Marjan M. Weiss, et al.. (2016). A novel CCM2 variant in a family with non‐progressive cognitive complaints and cerebral microbleeds. American Journal of Medical Genetics Part B Neuropsychiatric Genetics. 174(3). 220–226. 4 indexed citations
17.
Scheltens, Philip, Jos W. R. Twisk, Rafael Blesa, et al.. (2012). Souvenaid (R) Improves Memory in Drug-Naive Patients with Mild Alzheimer's Disease: Results from a Randomized, Controlled, Double-Blind Study (Souvenir II). Pure Amsterdam UMC. 3 indexed citations
18.
Vogels, Raymond L.C., Wiesje M. van der Flier, Barbera van Harten, et al.. (2007). Brain Magnetic Resonance Imaging Abnormalities in Patients with Heart Failure. European Journal of Heart Failure. 9(10). 1003–1009. 126 indexed citations
19.
Vogels, Raymond L.C., Philip Scheltens, Jutta M. Schroeder‐Tanka, & Henry C. Weinstein. (2006). Cognitive Impairment in Heart Failure: A Systematic Review of the Literature. European Journal of Heart Failure. 9(5). 440–449. 409 indexed citations
20.
Rombouts, Serge A.R.B., et al.. (1999). FMRI of visual encoding: Reproducibility of activation. Pure Amsterdam UMC. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by David S. Knopman Breakdown of academic impact, for papers by Ronald C. Petersen Breakdown of academic impact, for papers by Clifford R. Jack Breakdown of academic impact, for papers by John C. Morris Breakdown of academic impact, for papers by Michael W. Weiner Breakdown of academic impact, for papers by Bruce L. Miller Breakdown of academic impact, for papers by William J. Jagust Breakdown of academic impact, for papers by Frederik Barkhof Breakdown of academic impact, for papers by Steven T. DeKosky Breakdown of academic impact, for papers by Guy M. McKhann
Rankless by CCL
2026